Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Pathology

• Publication date

  2005-10-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/jcp.2005.025957PMID 16254105PMCID PMC1770768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein-protein interactions in the regulation of the extracellular signal-regulated kinase

  2005cited by this paper
• G1 cell-cycle control and cancer

  2004influential reference
• Epidemiology Of Cutaneous Melanoma And Current Trends

  2004cited by this paper
• Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

  2004cited by this paper
• Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

  2004cited by this paper
• Microarray expression profiling in melanoma reveals a BRAF mutation signature

  2004cited by this paper
• Cancer in New South Wales Incidence and Mortality 2003

  2004cited by this paper
• V599EB-RAF is an Oncogene in Melanocytes

  2004cited by this paper
• Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.

  2003cited by this paper
• Skin Pathology, 2nd ed.

  2003cited by this paper
• Apoptosis and melanoma chemoresistance

  2003cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling*

  2003cited by this paper
• Prognosis for patients with thin cutaneous melanoma

  2003cited by this paper
• Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma

  2003cited by this paper
• Overcoming resistance of cancer cells to apoptosis

  2003cited by this paper
• Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

  2003cited by this paper
• A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

  2003cited by this paper
• Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

  2003cited by this paper
• Apoptosis and melanoma: molecular mechanisms

  2003cited by this paper
• Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• The Bcl2 family: regulators of the cellular life-or-death switch

  2002cited by this paper
• Mitogen-actived protein kinase activation is an early event in melanoma progression.

  2002cited by this paper
• [Significance of MEK-ERK cascade in the development of human breast carcinoma].

  2002cited by this paper
• BAY 43-9006: early clinical data in patients with advanced solid malignancies.

  2002cited by this paper
• Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants

  2002cited by this paper
• Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate.

  2002cited by this paper
• Inhibitors of the ras oncogene as therapeutic targets.

  2002cited by this paper
• A matter of life and death.

  2002cited by this paper
• Apoptosis modulators as cancer therapeutics.

  2001cited by this paper
• Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

  2001cited by this paper
• Ras signaling pathway proteins as therapeutic targets.

  2001cited by this paper
• Ras and Rho regulation of the cell cycle and oncogenesis.

  2001cited by this paper
• Cancer in New South Wales: Incidence and mortality 1997.

  2001cited by this paper
• Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy.

  2001cited by this paper
• Blocking oncogenic Ras signaling for cancer therapy.

  2001cited by this paper
• Signal transduction pathway targets for anticancer drug discovery.

  2000cited by this paper
• MAP kinase pathways.

  1999cited by this paper
• Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

  1996cited by this paper
• Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma.

  1995cited by this paper
• A matter of life and death.

  1981cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Atlas of Tumour Pathology

  1952cited by this paper

• Berberine as a Multi‐Targeted Therapeutic Agent in Melanoma: Mechanisms, Efficacy, and Combination Therapies

  2025cites this paper
• L‐kynurenine and quinolinic acid inhibited markers of cell survival in B16 F10 melanoma cells in vitro

  2024cites this paper
• Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy

  2024cites this paper
• Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy

  2024cites this paper
• A de novo dual-targeting supramolecular self-assembly peptide against pulmonary metastasis of melanoma

  2023cites this paper
• PTEN: a novel target for vitamin D in melanoma.

  2022cites this paper
• Model Systems for the Study of Malignant Melanoma.

  2021cites this paper
• Cytoplasmic phosphorylated ERK1/2 expression in patients with melanoma is associated with tumor stage and metastasis

  2021influential citation
• Combining kinase inhibitors for optimally co‐targeting cancer and drug escape by exploitation of drug target promiscuities

  2020cites this paper
• Phenotypic melanoma heterogeneity is regulated through cell-matrix interaction-dependent changes in tumor microarchitecture

  2020cites this paper
• 3D in vitro cutaneous melanoma models

  2020cites this paper
• A Novel Bis-Coumarin Targets Multiple Tyrosine Kinases of Key Signaling Pathways in Melanoma and Inhibits Melanoma Cell Survival, Proliferation, and Migration

  2020cites this paper
• Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer

  2018cites this paper
• Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.

  2018cites this paper
• Modulation of human melanoma cell proliferation and apoptosis by hydatid cyst fluid of Echinococcus granulosus

  2018cites this paper
• Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines

  2018influential citation
• Metastatic melanoma moves on: translational science in the era of personalized medicine

  2017cites this paper
• Melanocytic nevi and melanoma: unraveling a complex relationship

  2017cites this paper
• Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway

  2017cites this paper
• Etlingera elatior Extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways

  2017cites this paper
• MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling, cell cycle regulators, and Ets-1-mediated MMP-2 expression.

  2016cites this paper
• THE EFFECT OF OXIDATIVE STRESS ON MITOCHONDRIAL ULTRASTRUCTURE AND IMMUNOEXPRESSION OF ERK-1 AND HIF-1 ALPHA IN ORAL EPITHELIAL DYSPLASIA INDUCED IN EXPERIMENTAL ANIMALS

  2016cites this paper
• Expression of phosphorylated extracellular signal-regulated kinase at the invasive front of hepatic colorectal metastasis

  2015cites this paper
• Protein disulfide isomerases: Impact of thapsigargin treatment on their expression in melanoma cell lines.

  2015cites this paper
• High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.

  2015cites this paper
• DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria

  2015cites this paper
• BRAF, KIT and NRAS mutations and expression of c‐KIT, phosphorylated extracellular signal‐regulated kinase and phosphorylated AKT in Japanese melanoma patients

  2015cites this paper
• Abstract. Raf-1 kinase inhibitory protein (RKIP), an endog- enous inhibitor of the extracellular signal-regulated kinase (ERK) pathway, suppresses metastasis in a number of cancer

  2015cites this paper
• Fonctions antitumorales de la voie ERK/MAPK et développement rationnel de nouvelles stratégies thérapeutiques

  2014cites this paper
• Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies

  2014cites this paper
• Real‐time cell cycle imaging during melanoma growth, invasion, and drug response

  2014cites this paper
• Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

  2014cites this paper
• Coexpression of SOX10/CD271 (p75NTR) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients

  2014cites this paper
• Oncogenes in melanoma: an update.

  2014cites this paper
• Immunohistochemical Detection of Aurora A and ERK Pathway in Oral Leukoplakia and Oral Squamous Cell Carcinoma

  2014cites this paper
• Regulation of apoptosis induced by targeting the RAF/MEK/ERK pathway in human melanoma

  2014cites this paper
• Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker

  2014cites this paper
• The role of MIF in melanoma progression

  2013cites this paper
• CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2

  2013cites this paper
• Activating kinase mutations in melanoma

  2013cites this paper
• Current and future trials of targeted therapies in cutaneous melanoma.

  2013influential citation
• Modeling Melanoma In Vitro and In Vivo

  2013cites this paper
• Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs

  2012cites this paper
• Melanoma Biomarkers

  2012cites this paper
• Preclinical Development Proteasome Inhibition Blocks NFk B and ERK 1 / 2 Pathways , Restores Antigen Expression , and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs

  2012cites this paper
• Specifically targeting ERK1 or ERK2 kills Melanoma cells

  2012cites this paper
• Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype

  2012cites this paper
• Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells

  2011cites this paper
• Title : Pathology laboratory in Formalin free system

  2011cites this paper
• The role of mitogen‐ and stress‐activated protein kinase pathways in melanoma

  2011cites this paper
• Genetic changes in melanoma progression

  2011cites this paper
• Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma

  2011cites this paper
• BRAF as a target for cancer therapy.

  2011cites this paper
• Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

  2010cites this paper
• Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells

  2010cites this paper
• PLX4032: does it keep its promise for metastatic melanoma treatment?

  2010cites this paper
• Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.

  2010cites this paper
• Preclinical Study of PI3K and BRAF Inhibitors in Malignant Melanoma

  2010cites this paper
• MUTATIONS AND MOLECULAR SIGNATURES IN HUMAN MELANOMA

  2010cites this paper
• Analysis of B-RafV600E Regulated MicroRNAs and Proteins in Melanoma

  2010cites this paper
• Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

  2010cites this paper
• Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells

  2009cites this paper
• Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

  2009cites this paper
• Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues

  2009cites this paper
• Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.

  2009cites this paper
• [Advances in molecular biology and their application in the diagnosis and treatment of melanoma].

  2009cites this paper
• CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion

  2009cites this paper
• Coexpression of major histocompatibility complex class II with chemokines and nuclear NFκB p50 in melanoma: a rational for their association with poor prognosis

  2009cites this paper
• Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis

  2009cites this paper
• Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma

  2009cites this paper
• Novedades en biología molecular y su aplicación en el diagnóstico y el tratamiento del melanoma

  2009cites this paper
• Small molecules and targeted therapies in distant metastatic disease

  2009cites this paper
• MAP kinase modulation in squamous cell carcinoma of the oral cavity.

  2009cites this paper
• Activated extracellular signal‐regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma

  2009cites this paper
• Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

  2009cites this paper
• In vitro three-dimensional tumor microenvironment models for anticancer drug discovery

  2008cites this paper
• Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.

  2008cites this paper
• Regulation of endoplasmic reticulum stress induced apoptosis in human melanoma.

  2008cites this paper
• Overcoming resistance to apoptosis in cancer therapy.

  2008cites this paper
• Targeting BRAF Activity as a Novel Paradigm for Melanoma Therapy

  2008cites this paper
• Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

  2008cites this paper
• The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  2008cites this paper
• Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas

  2008cites this paper
• Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.

  2008cites this paper
• Targeting BRAF/MEK in melanoma: new hope or another false dawn?

  2007cites this paper
• Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

  2007cites this paper
• Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.

  2007cites this paper
• Tumor Regression When Combined with Docetaxel ( ARRY-142886 ) Induces Growth Arrest in Melanoma Cells Signal-Regulated Kinase Kinase Inhibitor AZD 6244 The Mitogen-Activated Protein / Extracellular

  2007cites this paper
• The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

  2007cites this paper
• Is ERK activation a good biomarker for estradiol and tamoxifen effects?

  2007cites this paper
• Growth factors and oncogenes as targets in melanoma: lost in translation?

  2007cites this paper
• Extracellular signal‐regulated protein kinase is activated in cervical intraepithelial neoplasms but inactivated in invasive cervical carcinoma

  2006cites this paper
• Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.

  2006cites this paper
• Markers and tissue resources for melanoma: meeting report.

  2006cites this paper
• Malignant melanoma: genetics and therapeutics in the genomic era.

  2006cites this paper
• Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans.

  2006cites this paper
• IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway.

  2006cites this paper
• I mmunotherapy of melanoma – past , present and future

  year unknowncites this paper
• Coexpression of SOX 10 / CD 271 ( p 75 NTR ) and beta-galactosidase in large to giant congenital melanocytic nevi of pediatric patients

  year unknowncites this paper